Minor Use Minor Species Development of Drugs (R01)

US Food and Drug Administration (FDA) grant unknown #FOR-FD-24-013

Summary

This is a forecasted federal funding opportunity from the FDA (HHS) focused on the development of drugs for minor use and minor species (MUMS). The R01 grant mechanism suggests support for investigator-initiated research projects aimed at advancing drug development for underserved animal populations and niche therapeutic uses. The opportunity was forecasted as of November 30, 2023, with full details pending release. This aligns with the FDA's Minor Use and Minor Species Animal Health Act mandate to incentivize development of drugs that would otherwise lack commercial viability.

What they want

Support research and development of drugs intended for minor use (uncommon diseases or conditions in major animal species) and/or minor species (animals other than cattle, horses, swine, chickens, turkeys, dogs, and cats). Funding is via the R01 grant mechanism, indicating support for discrete, specified, circumscribed research projects in an area representing the investigator's specific interest and competencies.

How they evaluate

Submission: Grants.gov federal grants portal (grants.gov)

Risks & flags

Opportunity is in 'forecasted' status only — full solicitation details, eligibility requirements, and evaluation criteria are not yet available
No response deadline, award value, or scope specifics disclosed — insufficient information to fully assess competitiveness or potential wiring

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Minor Use Minor Species Development of Dru…

$unknown

Onboard ↗